The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery
Ece Turan-Vural¹, Banu Torun-Acar¹, S Argun Kivanc², Suphi Acar¹
¹Haydarpaşa Numune Education and Research Hospital, Ophthalmology Clinic, Istanbul, Turkey; ²Umranıye Education and Research Hospital, Ophthalmology Clinic, Istanbul, Turkey
Purpose: To investigate the role of postoperative topical 0.05% cyclosporine A (CsA) eye drops (Restasis®, Allergan Pharmaceutical) in the prevention of recurrence among patients with primary pterygium treated with bare-sclera technique.
Methods: In this prospective randomized controlled study, 36 eyes (34 patients) with primary pterygium were randomized into two groups: Group I comprised 18 eyes (18 patients), and Group II comprised 18 eyes (16 patients). Bare sclera technique was performed in both groups. In Group I, 0.05% CsA was administered postoperatively at 6-hour intervals for 6 months, and Group II did not receive any cyclosporine treatment. The patients were assessed for recurrence, side effects, and complications at postoperative 1 and 7 days as well as each month during the following year. Conjunctival advances which showed a limbus higher than 1 mm were recognized as recurrence.
Results: Recurrence occurred in four patients (22.2%) in Group I and in eight (44.4%) patients in Group II.
Conclusion: Postoperative application of low-dose CsA can be effective for preventing recurrences after primary pterygium surgery.
Keywords: primary pterygium, cyclosporine A, bare sclera
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.